UnitedHealth Group (NYSE: UNH) shares rallied sharply after the health insurance giant reported second-quarter earnings and signaled growing confidence in its financial recovery.
The company’s stock was trading near $416, approaching its highest level in roughly 11 months, as investors responded positively to the updated guidance.
UnitedHealth had already impressed Wall Street with a strong first-quarter performance in April, reporting adjusted earnings per share of $7.23 against consensus estimates ranging from $6.59 to $6.76.
That first-quarter beat represented roughly a 10% outperformance versus expectations, reinforcing the narrative that the company’s turnaround strategy was gaining real traction.
Following those results, UnitedHealth raised its full-year 2026 adjusted EPS guidance to greater than $18.25, up 50 cents from the prior forecast of greater than $17.75.
Analysts had been watching the second quarter closely, with Street estimates calling for revenue between $110 billion and $111 billion and adjusted earnings of $4.85 per share for the period.
Revenue was expected to run slightly lower year over year as the insurer shed lower-margin Medicaid business, but earnings were projected to jump approximately 19% as profitability improved.
The company’s Medical Care Ratio was expected to come in at 88.6% for the quarter, a modest improvement from 89.4% a year ago, a shift that carries significant margin implications at UnitedHealth’s scale.
UnitedHealth’s Optum unit stood out as a particular bright spot, with operating income forecast to jump nearly 8%, driven by growth across the Optum Health and Optum Rx platforms.
Piper Sandler analyst Jessica Tassan expected the company to raise its adjusted EPS guidance for a second time in 2026, powered by strong Medicare Advantage performance across both UnitedHealthcare and Optum Health units.
Tassan also indicated she believed UNH was on track to return to its long-term 13% to 16% adjusted EPS growth target in 2027, a milestone that would represent a full operational recovery.
UNH stock had climbed 32% year-to-date heading into the quarterly report, driven by the company’s margin improvement efforts and premium rate increases across its business lines.
Over the prior 52 weeks, UNH rose 32.8%, outpacing the S&P 500 Index’s 20.8% gain and the State Street Healthcare Select Sector SPDR ETF (XLV), which returned 14.6% over the same period.
Medical cost inflation had moderated meaningfully, and profitability within the Medicare Advantage segment showed tangible improvement, easing concerns that had previously weighed heavily on investor sentiment.
Management demonstrated greater command over claims variability, a factor that had previously unsettled the investment community, prompting multiple Wall Street firms to upgrade their outlooks for the stock.
